Investigating Dupilumab's Effect in Asthma by Genotype
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The Goal of this study is to investigate if individuals ages 12 years and older, carrying the
IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the
anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with
dupilumab on the rate of asthma exacerbations.
Phase:
Phase 4
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)